A Prospective Longitudinal Cohort Study of the Incidence of Hypertension and Arrhythmias In Patients Treated With Bruton's Tyrosine Kinase Inhibitors For Chronic Lymphocytic Leukemia Using Wearable Technology (SENTINEL)

NCT06211413 ENROLLING_BY_INVITATION

Acalabrutinib and Zanabrutinib are highly effective drugs used to treat Chronic Lymphocytic Leukemia, but they are associated with high blood pressure and abnormal heart rhythms. SENTINEL is an observational study that will use wearable technology to monitor heart rhythm and blood pressures at home to better understand how frequently patients are experiencing high blood pressure and/or abnormal heart rhythms.

Details

Lead sponsor	Abramson Cancer Center at Penn Medicine
Status	ENROLLING_BY_INVITATION
Enrolment	50
Start date	2024-02-07
Completion	2026-08

Conditions

• Chronic Lymphocytic Leukemia
• Atrial Fibrillation
• Hypertension
• Cardiotoxicity

Interventions

• no intervention

Primary outcomes

• Incidence of hypertension — 6 months
  New onset or worsening hypertension recorded on home blood pressure monitoring

Countries

United States